Patient- versus physician-reported outcomes in a low-dose tamoxifen trial in noninvasive breast cancer
{{output}}
Background: We recently conducted a de-escalation trial of low-dose tamoxifen 5 mg/day ("babytam", BT) or placebo given for 3 years in 500 women with noninvasive breast cancer. Women on babytam had a 52% reduction of recurrence (... ...
